Q4 2025 Prothena Corporation PLC Earnings Call Transcript
Key Points
- Prothena Corp PLC (PRTA) advanced two partner programs, pacilizumab andrame, into phase 3 clinical trials in 2025.
- Roche's phase 3 Pariio trial for Parkinson's disease and Novo Nordisk's phase 3 Cleopatra trial for ATTRCM are significant advancements.
- Prothena's collaborations with Bristol-Myers Squibb progressed, with BMS 986-446 obtaining fast track designation from the US FDA for Alzheimer's treatment.
- The company has a strong cash position with $308.4 million in cash and restricted cash as of year-end 2025.
- Prothena is eligible for up to $105 million in clinical milestone payments in 2026 from its partnerships with large pharmaceutical companies.
- Primary completion dates for key partnered program trials, such as Pariio and Cleopatra, are not expected until 2029, indicating a long wait for potential results.
- The company's net loss for 2025 was $244.1 million, which is substantial despite being in line with guidance.
- Prothena's PRX 12 showed non-competitive RAE rates compared to FDA-approved anti-A beta antibodies.
- The company faces significant competition in the Alzheimer's treatment space, with larger and more advanced competitors.
- Prothena's 2026 financial guidance does not include potential milestone payments, indicating uncertainty in revenue realization.
Good day, ladies and gentlemen, and welcome to the Prothena Biosciences 4th quarter and full year 2025 financial results conference call. My name is Jenny, and I will be your coordinator for today. (Operator Instructions)
I would now like to turn the presentation over to Mark Johnson, Vice President and head of investor relations at Prothena. Please proceed.
Thank you, operator. Good afternoon, everyone, and welcome to today's call to review Profina's business progress, fourth quarter and full year 2025 financial results, and 2026 financial guidance.
Please review the press release we issued earlier today, which is available on our website at propina.com and it's also attached to a Form 8k filed today with the SEC.
In addition, we're using supplemental slides which are available on our investors website, events, and presentation section.
On today's call, Dr. Gene Kenny, our President and executive officer, will provide opening remarks, including an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
